AGM AND TOUR OF FACILITY

The Magellan Stem Cells Annual General Meeting of was held in December at the Braeside premises where Magellan Chair, Lou Panaccio conducted a fruitful meeting for those in attendance and those online.
Several investors joined us after the meeting for a tour of the impressive new facility which was well received by all.

MAB MEETS, PROTOCOL PROGRESSES

Magellan’s Medical Advisory Board (MAB) has met and reviewed the latest draft protocol for the Phase three trial. The Board made some additions, and the protocol will now go through final appraisal by the Magellan product team before submission to the contract research organisation. The contract research organisation will review the protocol and develop a quote on providing the appropriate services.

TGA CORRESPONDENCE RE VISIT

Magellan previously reported that the Therapeutic Goods Administration (TGA) attended the Braeside facility to conduct a formal audit of the documentation Magellan will need to have in place for the application for a license for our GMP (Good Manufacturing Practice) Lab.
The TGA has formally corresponded with Magellan about the visit and the content was in line with the TGA’s December 23 draft.
No critical matters were raised and the TGA’s detail was consistent with its advice at the time of the visit.
Such areas that will need completion before licensing have been reinforced by Magellan and those that can be attended to as ongoing activity can be developed in time for a visit that will take place after licensing in a year’s time.

PATIENT TREATMENTS AT BH

Magellan patient treatments continue at Box Hill where there are many new appointments and a steady number of lipo-isolations, which will result in treatments in the coming months. There remains a strong demand for autologous treatments which augurs well for an allogeneic product, which will become available once a successful trial has been completed.

WELCOME BACK TO KIRAN

Magellan’s Head of Science, Ms Kiran Shah has returned from maternity leave late last year. We warmly welcome Kiran back to work to oversee many important activities at Braeside. Kiran was in attendance for the important meeting with the TGA in December and we were grateful that she was able to return from her leave to do this. Sincere thanks Kiran.

CAB MEET NOVEMBER

Our recently formed Corporate Advisory Board under the Chair of Richard Price and Board member Ross Williams has met and provided some valuable insights to our fund raising and connections with Government agencies.

CDMO ACTIVITY: MANUFACTURING

Magellan has been working on reviewing methods of cell culturing at the lab in preparation for the trial and the commencement of Magellan’s development of a Contract development manufacturing organisation that we anticipate will commence in early 2025.
There is great demand for cell manufacture worldwide and Magellan is ideally placed to generate substantial revenues from such activities.

Magellan will report on progress with this venture as matters develop.